Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim N01 for platelet engraftment after pediatric umbilical cord blood transplantation
ChiCTR2600134030Phase 4Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Oct 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of romiplostim in hematopoietic malignancies, sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Proportion of patients achieving platelet engraftment by day 35 post-transplantation. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on ChiCTR2600134030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600134030.